Estrogen Receptor Agonist Market - Top Companies and Manufacturers

  • Report ID: 4982
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Companies Dominating the Estrogen Receptor Agonist Landscape

    • AstraZeneca
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • ESTRIGENIX
    • Karo Healthcare AB
    • Merck KGaA
    • Vivesto AB
    • Oncternal Therapeutics
    • Pfizer Inc.
    • Tocris Bioscience
    • Tokyo Chemical Industry Co., Ltd

Browse Key Market Insights with Data Illustration:

In the News

  • Positive high-level findings from the FLAURA2 Phase III trial showed that Tagrisso (osimertinib) from AstraZeneca improved progression-free survival (PFS) among individuals with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) more significantly when combined with chemotherapy than when used alone.
  • On Thursday, October 27, and Friday, October 28, at the Grand Hyatt at San Francisco Airport, located at 55 South McDonnell Road in San Francisco, Estrigenix Therapeutics, Inc. presented new research on hormone replacement treatment.

Author Credits:  Radhika Pawar


  • Report ID: 4982
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of estrogen receptor agonist is evaluated at USD 4.59 Billion.

The estrogen receptor agonist market size was valued at USD 4.3 Billion in 2023 and is expected to exceed USD 11.01 Billion by the end of 2036, expanding at over 7.5% CAGR during the forecast period i.e., between 2024-2036. The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

Asia Pacific industry is set to have the highest growth by 2036, backed by growing geriatric population in this region.

AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, Merck KGaA, Vivesto AB, Oncternal Therapeutics, Pfizer Inc., Tocris Bioscience, Tokyo Chemical Industry Co., Ltd
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample